D Path’s QPOR™ Platform Selected to Predict Patients’ Responses to TherapyNEWTON, Mass., Jan. 22, 2026 (GLOBE NEWSWIRE) -- 4D ...
PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive vectorized gene therapies with minimally-invasive delivery technology, is pleased to announce the ...
The partnership aims to broaden research opportunities for patients and offer sponsors operational performance.
If promising results on a skin cancer vaccine from Moderna and Merck lead to a new launch, the Covid-19 era darling's stock ...
Multi-Specialty CNS Research Center Strengthens Trial Execution and Patient Diversity in Alzheimer's Agitation Study - POTOMAC, MD / ACCESS Newswire / January 22, 2026 / IGC Pharma, Inc. (NYSE America ...
Monthly injections, once-daily pills, and even lifelong gene therapies could soon become options for people looking to lose ...
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of ...
Bunnie XO shares her harrowing experience with an experimental weight-loss drug, describing severe depression and suicidal ...
Jaguar has received the initial $16M payment related to the company's recently executed US out-license agreement for ...
In the Phase 2b trials, this combination therapy achieved a 49% decrease in the risk of recurrence or death relative to ...
Journey Medical (DERM): microcap biopharma with cash-generating dermatology portfolio and high-upside Emrosi launch. Read here for more analysis.
The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback